Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Ivaltinostat
Price:
Purity: 95.0%
Stocking Period: 10 Day
Contact: Yang

936221-33-9

936221-33-9 structure

Name: CG-200745
Chemical Name: 2-Octenediamide, N1-[3-(dimethylamino)propyl]-N8-hydroxy-2-[(1-naphthalenyloxy)methyl]-, (2E)
CAS Number: 936221-33-9
Molecular Formula: C₂₄H₃₃N₃O₄
Molecular Weight: 427.53700
Catalog: Signaling Pathways Apoptosis MDM-2/p53
Create Date: 2017-07-05 06:18:09
Modify Date: 2024-01-05 22:50:07
CG-200745 is a potent HDAC inhibitor, with IC50s of <3 μM for sensitive non-small cell lung cancer (NSCLC) cell lines. CG-200745 induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of proteins encoded by p53 target genes, MDM2 and p21 (Waf1/Cip1) in human prostate cancer cells[1]. CG-200745 attenuates phosphorylation of p38 MAPK in kidneys and it has a renoprotective effect by suppressing renal fibrosis and inflammation in a unilateral ureteral obstruction (UUO) mouse model[2].

Name	2-Octenediamide, N1-[3-(dimethylamino)propyl]-N8-hydroxy-2-[(1-naphthalenyloxy)methyl]-, (2E)
Synonyms	cg 200745

Description	CG-200745 is a potent HDAC inhibitor, with IC50s of <3 μM for sensitive non-small cell lung cancer (NSCLC) cell lines. CG-200745 induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of proteins encoded by p53 target genes, MDM2 and p21 (Waf1/Cip1) in human prostate cancer cells[1]. CG-200745 attenuates phosphorylation of p38 MAPK in kidneys and it has a renoprotective effect by suppressing renal fibrosis and inflammation in a unilateral ureteral obstruction (UUO) mouse model[2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Apoptosis >> MDM-2/p53 Signaling Pathways >> MAPK/ERK Pathway >> p38 MAPK Signaling Pathways >> Cell Cycle/DNA Damage >> HDAC Signaling Pathways >> Epigenetics >> HDAC
Target	HDAC p53 p38 MAP kinase
In Vitro	CG-200745 (0-10 μM; 48 hours) reduces the Calu6 cells proliferation to 40% of untreated cells[1]. CG-200745 (3 μM; 1-24 hours) significantly increases Calu6 cells proportion in G2/M phase (69%)[1]. CG-200745 (0-10 μM; 1-24 hours) treatment with low concentration significantly increases the acetylation of histone H3 and H4 in Calu6 cells at various sites in a time-dependent manner up to 24 hours after treatment[1]. Cell Proliferation Assay[1] Cell Line: Calu6 cells Concentration: 0-10 μM Incubation Time: 48 hours Result: Reduced the cell proliferation to 40% of untreated cells. Cell Cycle Analysis[1] Cell Line: Calu6 cells Concentration: 3 μM Incubation Time: 1, 8, 12, 24 hours Result: Increased significantly cell proportion in G2/M phase (69%). Western Blot Analysis[1] Cell Line: Calu6 cells Concentration: 0-10 μM Incubation Time: 1, 4, 8, 12, 24 hours Result: Increased the acetylation of histone H3 and H4 at various sites in a time-dependent manner.
In Vivo	CG-200745 (p.o.; 30 mg/kg/day; for 7 days) attenuates oxidative stress, inflammatory cytokines, and adhesion molecules in UUO kidneys[2]. Animal Model: Male 8-week-old C57BL/6 J mice weighing 20~22 g of unilateral ureteral obstruction (UUO)[2] Dosage: 30 mg/kg Administration: P.o.; daily; for 7 days Result: Attenuated oxidative stress, inflammatory cytokines and adhesion molecules in UUO kidneys.
References	[1]. Chun SM, et al. Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells. PLoS One. 2015 Mar 17;10(3):e0119379. [2]. Choi HS, et al. Histone deacetylase inhibitor, CG200745 attenuates renal fibrosis in obstructive kidney disease. Sci Rep. 2018 Aug 1;8(1):11546.

Density	1.148±0.06 g/cm3 (20 °C, 760 mmHg)
Molecular Formula	C₂₄H₃₃N₃O₄
Molecular Weight	427.53700
Exact Mass	427.24700
PSA	90.90000
LogP	4.06050

936221-33-9	1370466-81-1
90149-95-4	87269-59-8
37360-75-1	77469-70-6
9042-11-9	37247-87-3
108381-22-2	130405-40-2
1158522-08-7	940364-43-2
134104-43-1	131615-57-1
6906-52-1	930439-75-1
1018584-77-4	1375289-11-4
849349-65-1	2741925-30-2